Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient Transfection
Authors:
- Agnes HajduczkiAHAgnes Hajduczki
- William C. ChangWCWilliam C. Chang
- Rafael De La BarreraRBRafael De La Barrera
- James F. WoodJWJames F. Wood
- Wei-Hung ChenWCWei-Hung Chen
- Elizabeth J. MartinezEMElizabeth J. Martinez
- Jaime L. JensenJJJaime L. Jensen
- Rajeshwer S. SankhalaRSRajeshwer S. Sankhala
- Clayton SmithCSClayton Smith
- Alexander AndersonAAAlexander Anderson
- Elaine B. MorrisonEMElaine B. Morrison
- Caroline E. PetersonCPCaroline E. Peterson
Open Access
Abstract
Background/Objectives: In response to the COVID-19 pandemic, we developed a vaccine candidate against SARS-CoV-2. Spike Ferritin Nanoparticle (SpFN) comprises 24 identical prefusion-stabilized spike proteins anchored to a self-assembled nanoparticle. Organized along the three-fold axis of the ferritin particle, eight SARS-CoV-2 spike trimers are presented per nanoparticle. Methods: Here, we describe the CGMP processes for manufacturing SpFN using transient transfection of Expi293F cells. Results: The final yield of SpFN was ~10 mg per liter of media supernatant. The resulting protein is stable in cold storage for two years at −20 °C, as well as for a month at room temperature, and can withstand multiple freeze/thaw cycles. SpFN material produced using the CGMP protocols adjuvanted with Army Liposomal Formulation-QS-21 (ALFQ) elicited potent neutralizing antibodies against WA-1, Alpha, Beta, and Delta variants in mice as measured by a pseudovirus neutralization assay. Conclusions: This work demonstrates rapid development and scaled-up production of clinical-grade SARS-CoV-2 vaccine protein material, allowing permissive storage and transport conditions, and serves as a framework for recombinant protein production for future emergent pathogens.Keywords
Funding Information
- U.S. Department of War (W81XWH-18-2-0040)
This publication has 60 references indexed in Scilit:
- Transforming vaccinologyCell, 2024
- Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trialsEBioMedicine, 2022
- Humoral and cellular immune memory to four COVID-19 vaccinesCell, 2022
- SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicityCell Reports, 2021
- Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesCell, 2021
- Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1Applied Microbiology and Biotechnology, 2021
- Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2Cell, 2020
- Biophysical characterization of polydisperse liposomal adjuvant formulationsBiochemical and Biophysical Research Communications, 2020
- cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV‐1 envelope glycoprotein vaccine candidateBiotechnology and Bioengineering, 2017
- Experience with hepatitis A and B vaccinesThe American Journal of Medicine, 2005